Chemoinformaics analysis of (+)-alpha-phellandrene
| Molecular Weight | 136.238 | nRot | 1 |
| Heavy Atom Molecular Weight | 120.11 | nRig | 6 |
| Exact Molecular Weight | 136.125 | nRing | 1 |
| Solubility: LogS | -3.985 | nHRing | 0 |
| Solubility: LogP | 3.857 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 26 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 27.3687 |
| nHD | 0 | BPOL | 16.0513 |
| QED | 0.519 |
| Synth | 3.505 |
| Natural Product Likeliness | 2.835 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.013 |
| HIA | 0.005 |
| CACO-2 | -4.383 |
| MDCK | 0.0000239 |
| BBB | 0.835 |
| PPB | 0.920114 |
| VDSS | 2.963 |
| FU | 0.0774795 |
| CYP1A2-inh | 0.258 |
| CYP1A2-sub | 0.471 |
| CYP2c19-inh | 0.178 |
| CYP2c19-sub | 0.93 |
| CYP2c9-inh | 0.142 |
| CYP2c9-sub | 0.337 |
| CYP2d6-inh | 0.059 |
| CYP2d6-sub | 0.832 |
| CYP3a4-inh | 0.274 |
| CYP3a4-sub | 0.639 |
| CL | 12.66 |
| T12 | 0.617 |
| hERG | 0.024 |
| Ames | 0.011 |
| ROA | 0.038 |
| SkinSen | 0.94 |
| Carcinogencity | 0.344 |
| EI | 0.957 |
| Respiratory | 0.855 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.938956 |